Literature DB >> 18466989

Statin therapy and contrast-induced nephropathy after primary angioplasty.

Alberto Bouzas-Mosquera, José M Vázquez-Rodríguez, Ramón Calviño-Santos, Nicolás Vázquez-González, Alfonso Castro-Beiras.   

Abstract

A recent study suggested that statin therapy may prevent contrast-induced nephropathy (CIN) following primary angioplasty. Our aim was to assess the effect of statins in this setting in a larger population. We evaluated 589 consecutive patients with acute myocardial infarction who underwent primary angioplasty at our institution. Contrast-induced nephropathy was defined as an increase in serum creatinine by > or =0.5 mg/dL within 72 h following the procedure. Overall, 69 patients (11.9%) developed CIN. The incidence of CIN in the group on statins was 15.9%, as compared with 10.8% in the group not taking statins (p=0.2). Thus, we did not observe a protective effect of statin therapy on CIN development after primary angioplasty.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18466989     DOI: 10.1016/j.ijcard.2007.12.122

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

1.  Statin treatment before percutaneous cononary intervention.

Authors:  Mario Leoncini; Anna Toso; Mauro Maioli; Francesco Tropeano; Francesco Bellandi
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

2.  Obesity is not associated with contrast nephropathy.

Authors:  Navin Jaipaul; Rendell Manalo; Seyed-Ali Sadjadi; James McMillan
Journal:  Ther Clin Risk Manag       Date:  2010-05-25       Impact factor: 2.423

3.  Atorvastatin and prevention of contrast induced nephropathy following coronary angiography.

Authors:  Peyman Bidram; Farshad Roghani; Hamid Sanei; Zahraparin Hedayati; Allahyar Golabchi; Mehdi Mousavi; Alireza Hajiannejad; Behrouz Pourheidar; Mehdi Mohseni Badalabadi; Maryam Gharaati; Mohammadreza Akhbari; Asieh Salesi
Journal:  J Res Med Sci       Date:  2015-01       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.